Vanguard
http://www.vanguard.com/Vanguard, an investment management company, offers mutual funds and other financial products and services to institutional and individual investors worldwide.
View Older Stories View More Recent Stories
-
Vibrant Capital Announces Strategic Partnership with the University of North Texas
-
The Baldwin Group Launches Azimuth Re, Ltd., a Member-Owned Group Captive for Construction Leaders
-
Form N-MFP3 VANGUARD VARIABLE INSURA For: Mar 31
-
Form N-MFP3 VANGUARD MONEY MARKET For: Mar 31
-
Form N-MFP3 VANGUARD MONEY MARKET For: Mar 31
-
Form N-MFP3 VANGUARD CMT FUNDS For: Mar 31
-
Form N-MFP3 VANGUARD MUNICIPAL BOND For: Mar 31
-
Form N-MFP3 VANGUARD CALIFORNIA TAX- For: Mar 31
-
Form N-MFP3 VANGUARD NEW YORK TAX-FR For: Mar 31
-
Form N-MFP3 VANGUARD ADMIRAL FUNDS For: Mar 31
-
Steve Holman Joins Retirement Clearinghouse as SVP of PSN Strategy & Development to Accelerate Plan Sponsor Adoption of Auto Portability
-
Apica Delivers Agentic-Ready Telemetry Infrastructure for the AI Era
-
Form SCHEDULE 13G CENTERSPACE Filed by: VANGUARD PORTFOLIO MANAGEMENT LLC
-
Village Farms begins CFO succession plan, Ruffini to lead M&A efforts
-
Village Farms Announces Succession Plan for Chief Financial Officer
-
Alexandria Real Estate Equities, Inc. Named One of the Most Trustworthy Companies in America by Newsweek for Fourth Consecutive Year
-
Form 8-A12B VANGUARD WORLD FUND
-
Form 8-A12B VANGUARD WORLD FUND
-
Hart InterCivic’s Verity Vanguard™ Voting System Earns State Certification in Texas
-
Adagene prices $70 million public offering at $3.75 per ADS
-
Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs
-
Adagene partners with Incyte for cancer drug combination study
-
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable
-
Adagene reports higher response rates with increased muzastotug dosing
-
Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Re
-
Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update
-
Form 497J VANGUARD PENNSYLVANIA
-
Form NPORT-P VANGUARD MUNICIPAL BOND For: Jan 31
-
Form NPORT-P VANGUARD MUNICIPAL BOND For: Jan 31
-
Form NPORT-P Vanguard Charlotte Funds For: Jan 31
-
Form NPORT-P Vanguard Charlotte Funds For: Jan 31
-
Form NPORT-P VANGUARD WHITEHALL FUNDS For: Jan 31
-
Form NPORT-P VANGUARD TRUSTEES' EQUIT For: Jan 31
-
Form NPORT-P VANGUARD STAR FUNDS For: Jan 31
-
Form NPORT-P VANGUARD INTERNATIONAL For: Jan 31
-
Form NPORT-P VANGUARD MUNICIPAL BOND For: Jan 31
-
Form NPORT-P VANGUARD INTERNATIONAL For: Jan 31
-
Form NPORT-P VANGUARD INTERNATIONAL For: Jan 31
-
Form NPORT-P VANGUARD WHITEHALL FUNDS For: Jan 31
-
Form NPORT-P VANGUARD WHITEHALL FUNDS For: Jan 31
-
Form NPORT-P VANGUARD WHITEHALL FUNDS For: Jan 31
-
Form NPORT-P VANGUARD EXPLORER FUND For: Jan 31
-
Form NPORT-P VANGUARD MUNICIPAL BOND For: Jan 31
-
Form NPORT-P VANGUARD INTERNATIONAL For: Jan 31
-
Form NPORT-P VANGUARD MUNICIPAL BOND For: Jan 31
-
Form NPORT-P VANGUARD FIXED INCOME For: Jan 31
-
Form NPORT-P VANGUARD FIXED INCOME For: Jan 31
-
Form NPORT-P VANGUARD MUNICIPAL BOND For: Jan 31
-
Form NPORT-P VANGUARD WHITEHALL FUNDS For: Jan 31
-
Form NPORT-P VANGUARD WHITEHALL FUNDS For: Jan 31

